Patient Resources
what-is-tbe
Patient Resources
Additional Resources
It’s important that you’re able to stay as informed as possible, especially when you plan on traveling to countries in Europe and Asia that have had reported cases of TBE or TBEV infected ticks. Explore the links below to learn about TBE and how you can protect yourself and loved ones while traveling.
Consumer-Brochure
Consumer Brochure
Read up on some quick facts about TBE, what patients experience, and how to protect yourself from the virus.

DOWNLOAD
WHO Article
CDC Article
Read the CDC’s guidance regarding TBE vaccination.

VISIT
Vaccines by country
TBE Virus by Country
View where a TBE virus vaccine may be needed before traveling.

VISIT
Watch to Learn More about TBE Prevention
How to prevent TBE
TBE currently has no cure, and once infected, can only have the symptoms managed.1 Watch the video to learn everything you need to know about how to prevent yourself and loved ones from contracting TBE while traveling to European and Asiatic countries where TBE has been reported. Additionally, you’ll learn ways to help ensure that tick bites don’t occur, even while traveling in woodland or grassy areas.
What should you do if bitten by a tick?
In the event that you’re bitten by a tick, use a pair of fine-tipped tweezers and pull the tick out as close to the skin as possible.2 Rub the local area with rubbing alcohol or warm soap and water.2 If possible, place the tick in a sealed bag or container to bring to your healthcare provider for identification.2 Lastly, observe the presence of any abnormal symptoms you might experience.2 Contact your healthcare provider immediately if abnormal symptoms present themselves.2
find a ticovacfind a ticovac
Find TicoVac™ 
​​​​​​​Near You
The best place to get international travel health information specific to you and your travel plans is to contact your healthcare provider or pharmacist.

FIND TICOVAC™
References
  1. Dobler G, Erber W, Bröker M, Schmitt HJ, eds. The TBE Book. 4th ed. Global Health Press; 2021.
  2. Travel Health Pro. Insect and tick bite avoidance. Accessed February 24, 2022. https://travelhealthpro.org.uk/factsheet/38/insect-and-tick-bite-avoidance.

IMPORTANT SAFETY INFORMATION AND INDICATION

Important Safety Information
  • TicoVac™ should not be given to anyone with a history of a severe allergic reaction after a previous dose of TicoVac™. 
  • TicoVac™ may not protect all individuals against TBE.
  • Some individuals with weakened immune systems may have a reduced immune response.
  • TicoVac™ contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases.
  • The most common adverse reactions in subjects 1 through 15 years of age who received TicoVac™ were local tenderness, local pain, headache, fever, and restlessness.
  • The most common adverse reactions in subjects 16 through 65 years of age who received TicoVac™ were local tenderness, local pain, fatigue, headache, and muscle pain.
  • Tell your healthcare provider if you are pregnant, or plan to become pregnant.
  • Ask your healthcare provider about the risks and benefits for TicoVac™. Only a healthcare provider can decide if TicoVac™ is right for you.
Indication

TicoVac™ is a vaccine indicated for active immunization to prevent tick-borne encephalitis (TBE) and is approved for use in individuals 1 year of age and older.

You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

IMPORTANT SAFETY INFORMATION AND INDICATION

Important Safety Information
  • TicoVac™ should not be given to anyone with a history of a severe allergic reaction after a previous dose of TicoVac™. 
  • TicoVac™ may not protect all individuals against TBE.
  • Some individuals with weakened immune systems may have a reduced immune response.
  • TicoVac™ contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases.
  • The most common adverse reactions in subjects 1 through 15 years of age who received TicoVac™ were local tenderness, local pain, headache, fever, and restlessness.
  • The most common adverse reactions in subjects 16 through 65 years of age who received TicoVac™ were local tenderness, local pain, fatigue, headache, and muscle pain.
  • Tell your healthcare provider if you are pregnant, or plan to become pregnant.
  • Ask your healthcare provider about the risks and benefits for TicoVac™. Only a healthcare provider can decide if TicoVac™ is right for you.
Indication

TicoVac™ is a vaccine indicated for active immunization to prevent tick-borne encephalitis (TBE) and is approved for use in individuals 1 year of age and older.

You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

This site is intended only for U.S. residents. The products discussed in this site may have different product labeling in different countries.

The information provided is for educational purposes only and is not intended to replace discussions with a healthcare provider.

  • © 2022 Pfizer Inc.
  • All rights reserved.
  • Pfizer Inc. PO Box 29387, Mission, KS 66201
  • May 2022
  • PP-TCV-USA-0043
  • PP-TCV-USA-0043
  • PP-TCV-USA-0043